Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Nvidia! Turnaround for Nel, Saturn Oil & Gas, Lufthansa, TUI?

It looks like a peak is forming in artificial intelligence. The most prominent share here is Nvidia (NDAQ:NVDA) . With a spectacular rally, the value has surged by more than 100 per cent in just six months. However, the share price is now stuttering, and there have been ...
André Will-Laudien | April 18, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Medicus Pharma advances cancer treatment towards phase II trial

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Our next company is Medicus Pharma Ltd. (TSXV:MDCX) , headquartered in Philadelphia, Pennsylvania. The company is a publicly traded clinical stage, multi-st...
Ryan Dhillon | January 22, 2024 |

17 best payday loans online: Quick cash and fast approval this Christmas

If you face a financial emergency, traditional loans may not be a viable option if you have bad credit. So what can you do when you need quick cash – especially close if you need cash for Christmas gifts during the festive season? The best online payday loans are an a...
Dominic Castleberry | December 11, 2023 |

Retail advertising and AI-driven security solutions company growing rapidly

The location-based technology provider INEO Tech Corp. (TSXV:INEO) started growing its business right here in Canada but has since expanded to 23 states across the United States and even Colombia. The company has managed to combine advertising at storefront entran...
Brieanna McCutcheon | November 16, 2023 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

A great time for a uranium project generator business model

Welcome to the Market Herald’s Capital Compass. Our next guest is spearheading a team with a proven track record of uranium discoveries in the Athabasca Basin. Joining us today is John Bey, CEO of Standard Uranium Ltd. (TSXV:STND), who is here to t...
Brieanna McCutcheon | October 4, 2023 |

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...
Brieanna McCutcheon | September 19, 2023 |

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |
1 2 3 4 5 6 7 8 9 10 ...